Hawaii Biotech

About Us


HBI has built a management team with relevant experience at companies such as GlaxoSmithKline, QED Technologies, and Johnson & Johnson. Collaborators, past and present, include scientists from Harvard Medical School; the University of Texas Medical Branch, Galveston; the University of Hawaii; the Walter Reed Army Institute of Research; the U.S. Army Medical Research Institute for Infectious Disease (USAMRIID); the Southwest Foundation for Biomedical Research; and the Centers for Disease Control and Prevention.

The Company is committed to the development of the highest quality products with superior efficacy as demonstrated through the various stages of clinical trials. We plan to partner and license our vaccine candidates after safety and immunogenicity data has been obtained from clinical studies. Licensing and partnering our protein production capabilities at this time is also being considered. We are also funding the development of our vaccine pipeline from grants and contracts for public and private sources. This strategy allows us to maintain a stream of revenues from these sources well before FDA approval.

Hawaii Biotech will continue to rely on its internal research pipeline, supported primarily by grant revenues and supplemented by a strategic in-licensing program, to produce additional proprietary clinical development vaccine candidates. HBI has a strong track record of securing research funds from the National Institute of Health and the Department of Defense to support its research programs and is currently engaged in pre-clinical development of a tick borne encephalitis virus vaccine funded by a grant from the NIAID.

HBI also owns a saponin adjuvant, GPI-0100. The GPI-0100 adjuvant is useful in helping to elicit broad immune responses to certain vaccines and therapeutics especially in the cancer area. HBI has licensed the rights for use of the adjuvant to companies, (including for use with certain animal health and cancer vaccines) and is open to additional licensing opportunities for the GPI-0100 adjuvant.

The Company’s progress has been financed by private equity funding, as well as over $50 million in federal funding. As the costs associated with developing vaccines are substantial, we will continue to seek additional sources of funding by way of equity financing, licensing, grants, and other opportunities.


Employee Email Employee Email